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doi:10.1016/j.ejvs.2010.12.003Abstract Objectives: The aim of this study was to investigate the effect of a red-vine-leaf
extract (AS195, Antistax, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany)
on the volume of the leg and clinical symptoms in patients with chronic venous insufficiency
(CVI).
Design, materials and methods: A multicentre, randomised, double-blind and placebo-
controlled study was carried out with 720 mg AS195 per day over 12 weeks in CVI patients
(CEAP Grades 3e4a) and moderate-to-severe clinical symptoms. Efficacy endpoints were
changes in limb volume determined by water displacement volumetry, clinical CVI symptoms
assessed on a 10-cm visual analogue scale and global efficacy evaluations.
Results: The full-analysis set included 248 patients (placebo: nZ 122; AS195: nZ 126). After
12 weeks, AS195 significantly reduced lower limb volume by a mean of 19.9 standard error (SE)
8.9 ml over placebo (95% confidence interval (CI): 37.5, 2.3; pZ 0.0268; analysis of covari-
ance, ANCOVA). The standardised effect size of 0.28 for volume reduction indicates a clinically
relevant effect. On Day 84, the symptom of ‘pain in the legs’ assessed by visual analogue scale
decreased in the AS195 group compared with the placebo group: mean difference 6.6 SD
3.3 mm (95% CI: 13.1,0.1; p Z 0.047). Other symptoms showed no significant change.
The tolerability of AS195 was similar to that of placebo.@ukb.uni-bonn.de (E. Rabe), M.Stuecker@derma.de (M. Stu¨cker), Anke.Esperester@boehringer-
rd.Schaefer@boehringer-ingelheim.com (E. Scha¨fer), volumetry@vicron.de (B. Ottillinger).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Study with a Red-vine-leaf Extract in CVI 541Conclusions: AS195 treatment for 84 days resulted in an approximately 20 ml reduction of limb
volume in the active treatment group compared with the placebo group. Patients reported
subjective improvement following treatment with AS195 compared with placebo. However,
patients’ overall rating of efficacy did not correlate well with measured reductions in limb
volume.
Trial Registration: ClinicalTrials.gov NCT00855179.
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population; its prevalence is approximately 17%.1e3 Typical
clinical manifestations include oedema, venous eczema,
skin hyperpigmentation, white atrophy and venous ulcers.4
Anti-oedema drugs are used to treat leg oedema, pain,
tired, heavy legs and other subjective symptoms, but few
have shown safety and efficacy in mild-to-moderate CVI.
Among these are horse-chestnut-seeds extracts, hydrox-
yethylrutosides, Daflon (Servier, France) and red-vine-leaf
extract AS195 (Antistax; Boehringer Ingelheim Pharma
GmbH & Co. KG, Ingelheim, Germany).5e9 The pharmaco-
logical effect of AS195 is attributed mainly to its content in
flavonols, such as quercetin glucoside, kaempferol gluco-
side and quercetin glucuronide; the extract as a whole is
considered to be the active ingredient.
AS195 has shown efficacy in the treatment of CVI
symptoms in previous studies.8,9 We conducted the study
presented here to confirm the efficacy and tolerability of
film-coated tablets with AS195.
Material and Methods
The study was performed according to International
Conference on HarmonisationeGood Clinical Practice
(ICHeGCP) and observed the principles of the Declaration
of Helsinki. It was authorised by and notified to the relevant
national authorities and was started after approval from
the Ethics Committees of the institutions involved. The
study was performed under the EudraCT-No 2008-003932-40
(ClinicalTrials.gov-No NCT00855179).
Participants
Investigators informed patients orally and in writing and
obtained written consent before screening patients for
eligibility. Twenty sites in Germany recruited male or
female patients with CVI who were 18 years of age or older
with CEAP (Clinical Etiological Anatomical Pathophysiolog-
ical) Grades 3 (oedema) or 4a (mild skin changes caused by
venous disease, e.g., pigmentation and venous eczema).
Patients were assessed by phlebologists, who were usually
dermatologists specialising in phlebology. Those included
had to have stable oedema, defined as pretibial pitting
after digital compression and reproducible swelling
(difference of <150 g of displaced water over the 2-week
run-in period). Patients were required to have moderate-
to-severe varicose veins and leg pain of 3-cm intensity on
a 10-cm visual analogue scale (VAS). Patients with
concomitant diseases or treatments possibly influencing
study endpoints were excluded: these were patients with
decompensated cardiac failure, non-venous oedemas,peripheral arterial disease (ankle/arm pressure index
<0.9), acute phlebitis, thrombosis, florid venous ulcer,
lipodermatosclerosis, renal insufficiency, treatment with
venoactive drugs within the preceding 4 weeks, compres-
sion therapy or support stockings within the previous 2
weeks and venous surgery or sclerotherapy of the measured
limb within the previous 3 months. Patients with an
unstable response to or changes in cardiovascular drugs or
laxatives within the fortnight before screening were
excluded as well as women with changes in or initiation of
postmenopausal hormone replacement therapy within the
previous 3 months, pregnant or nursing women or women of
childbearing potential and inadequate birth control.
Interventions, randomisation, blinding and
concealment of allocation
After a 2-week run-in period on placebo, patients were again
screened for eligibility and then randomised in a balanced
fashion to 12 weeks of oral treatment with two film-coated
tablets per day. The tablets contained 360mg tablet1 AS195
for the active treatment group (total daily dose: 720 mg
AS195) or look- and taste-alike placebo for theplacebo group.
Patients received the medication box with the next
available number at the site. The allocated treatment
group was determined according to the randomisation
code. A department of the study sponsor not involved in
study performance prepared this code using validated
software. Treatment allocation was concealed and patients
and study personnel at sites, sponsor and clinical research
organisation (CRO) were blinded to treatment assignment
until after database lock.
Study objectives, schedule and outcomes
This study assessed the tolerability of film-coated tablets
containing AS195 and their efficacy in reducing lower limb
oedema and in improving subjective symptoms in CVI
patients. Patients had to come to the study centres at the
same timeoneach visit, if feasible in the late afternoon. Visits
were scheduled onDay 14 (Screening, start of run-in), Day 0/1
(start of therapy) and Days 21, 42 and 84 (within 3 days).
The primary efficacy variable was the change in volume of
the more severely affected limb from baseline until Day 84,
measured as weight of displaced water. All measurements
were carried out after 45 min resting for thermoregulatory
and cardiovascular adaptation (sitting position), and at
standardised room temperature. The leg was inserted into
a specially designed container filled with water at 34 C to
a level of 28 cm.Overflowingwater displaced by inserting the
legwas collected in a plastic beaker. Theweight of displaced
542 E. Rabe et al.water was recorded and documented on a digital scale with
a printer. The weight of water displaced can be used to
calculate limb volume from the specific gravity of water
(0.993 g ml1 at 34 C; this article uses g and ml inter-
changeably). All measurements were performed twice
within 5e10 min, or three times, if the first and second
measurements differed by >20 g. The statistical analyses
were based on the arithmetic mean of the measurements.
Study staff performing volumetry were trained before the
study. Values of single measurements were monitored
throughout the study, and, if variability indicated difficul-
ties, the staff were supervised and retrained.
Secondary efficacy variables were the change in volume
of the more affected limb from baseline until Days 21 and
42, the change of calf circumference from baseline until
Days 21, 42 and 84, the change in subjective CVI symptoms
(tired, heavy legs; sensation of tension; and leg pain
attributable to CVI) from baseline until Days 21, 42 and 84
(10-cm VAS), the time to improvement of subjective CVI
symptoms (0e2e5e10e20 days, no improvement) and the
global efficacy assessments by patients and investigators
(4-point verbal rating scale (VRS); Day 84).
Safety endpoints included adverse events (AEs), safety
laboratory evaluations (blood chemistry and haematology),
vital signs (pulse rate and blood pressure) and the global
tolerability assessments by patients and investigators (4-
point VRS; Day 84).
Concomitant therapy
Patients had to minimise or avoid, if possible, analgesic, anti-
inflammatory (topical and systemic non-steroidal anti-
inflammatorydrugsor systemiccorticosteroids),anti-migraine
medication (including ergot alkaloids) and psychotropic drugs.
High doses of laxatives, compression therapy, diuretics,
nitrates and other vasoactive, circulatory or CVI drugs were
inadmissible.
Sample size and statistics
The sample size estimate was based on a previous similar
study in a comparable population.9 A treatment difference
of 42.2 g at Day 84 vs. baseline in the AS195 group, no
effect in the placebo group and a common SD of 100 g were
assumed. To detect an effect of that magnitude with 90%
power with a two-sided 5% significance level, 119 patients
per group were required. Consequently, the study aimed to
include 120 treated patients per group (total 240 patients).
Missing efficacy data were replaced by the ‘last obser-
vation carried forward’ (LOCF) procedure. The least
favourable category was assigned to missing entries for the
global assessment of tolerability or efficacy, if missing data
were due to withdrawal or dropout due to poor efficacy,
poor tolerability or AEs.
Differences between the treatment groups with regard to
the primary endpoint ‘change from baseline in the limb
volumeat Day 84’were tested using an analysis of covariance
(ANCOVA), including centre and baseline as covariables and
the factor treatment. Least-square means, adjusted for
centre and baseline values, were calculated for both groups
and compared between AS195 and placebo. A two-sided 95%confidence interval (CI) was calculated for the treatment
contrast of interest. Treatment by centre interaction was
investigated in a sensitivity analysis. The primary analysis
was based on the full-analysis data set (FAS). An evaluation
with the per-protocol data set (PPS) was carried out for the
primary endpoint to support the results for the FAS.
For continuous secondary endpoints (change from base-
line in limb volumes at Days 21 and 42; in calf circumference
and in subjective CVI symptoms at Days 21, 42 and 84), the
same statistical method as for the primary endpoint was
used. Wilcoxon’s rank test was used for the evaluation of the
time to improvement of symptoms and the global efficacy
and tolerability assessments by patients and investigators.
AEs were coded in MedDRA 12.1 and tabulated to
compare incidences across treatment groups. Changes in
vital signs, laboratory values, physical examinations or
other safety relevant data were summarised by treatment
group and compared descriptively. All statistical analyses
were performed with SAS Version 8.02.
Results
Participants
Between April and November 2009, 20 centres enrolled 283
patients; 250 patients entered the study, 123 were rando-
mised to placebo and 127 to AS195. One patient allocated
to either group was not treated (lactose intolerance and
loss to follow-up immediately after randomisation).
Seventeen patients (6.9%) discontinued the trial prema-
turely, 10 in the placebo (8.2%) and 7 in the AS195 group
(5.6%). The reason was AEs in five placebo patients and in
one AS195 patient. Fig. 1 illustrates the flow of participants
and the reasons for premature discontinuation. The FAS
included the 248 patients (placebo: n Z 122; AS195:
n Z 126), who were treated and provided data for the
primary endpoint.
Significant protocol violations were found in both trial
arms at a similar frequency, that is, 11 patients (9% of the
FAS) in the placebo and 13 (10%) in the AS195 group. The
reasons were incorrect duration of treatment (n Z 9 and
n Z 9 in the placebo and in the AS195 group, respectively;
multiple reasons possible), prohibited concomitant medi-
cation (n Z 3; n Z 3), non-compliance with run-in medi-
cation (n Z 2; n Z 3), violation of an inclusion criterion
(nZ 0; nZ 4) and incorrect timing of visits (nZ 1; nZ 2).
All 24 patients (10%) with important protocol deviations
were excluded from the PPS, which comprised 224 patients
(90% of the FAS), 111 (91%) in the placebo and 113 (90%) in
the AS195 group.
Demography and baseline data
Most study patients were female (n Z 202 of 248; 81.5%),
the mean age was 58 SD 13 years (range: 21e87 years). The
patient population was largely overweight with a mean
body mass index (BMI) of 28.3 SD 5.2 kg m2. More patients
in the AS195 group were female than in the placebo group
(84% vs. 79%). Otherwise, there was no significant differ-
ence in demographic parameters between treatment
groups.
Figure 1 Flow of participants in the study.
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Overall, 64% had a CEAP score of 3, 36% a score of 4a. The
mean CVI duration was 11.5 SD 13 years (range: 0e49 years).
Most participants had moderate leg oedema (78%;
severe: 22%). Varicose veins were rated moderate in 79% of
the trial population and severe in 21%. Hyperpigmentation
(any intensity) was present in 57%. One-quarter (24%) had
eczema, generally of mild intensity. Almost all patients
(97%) had telangiectases or reticular veins (mild or
moderate: 89%; severe: 8%).
Overall, 29% of patients had received treatment for CVI
in the 3 months before the study (placebo: 35%; AS195:
22%). Most frequently, these were compression stockings
(placebo: 20%; AS195: 13%).The baseline efficacy variables were similar in both
treatment arms and are tabulated in Table 1. The mean
values for the three subjective CVI symptoms were
approximately 6 cm on the 10-cm VAS, which confirms that
the majority of patients were at least moderately
affected.
Efficacy
Results in this section relate to the FAS and ANCOVA,
adjusting for centre effect and baseline value, if applicable.
Negative differences between treatment groups indicate
a superiority of AS195. The results for the PPS were similar,
but tended to show the superiority of AS195 more clearly.
Table 1 Baseline efficacy variables (Full Analysis Set), All data: mean and standard deviation (S.D.).
Placebo AS195
Patients N Z 122 N Z 126
Mean limb volume as weight of displaced water [g] 2339.4 SD 324.0 2306.2 SD 362.5
Range 1658e3597 1646e3768
Calf circumference [cm]
Mean, SD 40.3 SD 3.8 39.9 SD 4.1
Range 30e51 33e55
Tired heavy legs [0e10 cm VAS]
Mean, SD 6.0 SD 2.1 5.9 SD 2.0
Range 0.0e10.0 0.0e9.9
Sensation of tension in the legs [0e10 cm VAS].
Mean, SD 5.9 SD 2.2 6.0 SD 2.0
Range 0.3e10.0 0.3e9.8
Pain in the legs [0e10 cm VAS]
Mean, SD 6.3 SD 1.9 6.2 SD 1.8
Range 3.0e10.0 1.2e9.8
544 E. Rabe et al.In placebo patients, mean limb volume decreased by 7.2
SE 6.9 ml from baseline during the study, in the AS195 group
by 27.1 SE 6.8 ml (Table 2). The mean difference between
these groups reaches statistical significance.
The AS195 group showed a linear improvement of leg
oedema over time, whereas patients receiving placebo
showed a slight increase of leg oedema between Days 21
and 42, followed by a reduction after Day 42 (see Fig. 2).
The difference between groups was 2.6 SE 6.7 ml (95% CI:
15.8, 10.7) at Day 21 (p Z 0.702) and 17.0 SE 8.6 ml at
Day 42 (95% CI: 34.1, 0.0; p Z 0.05).
Centre effects and treatment by centre interactions
were not significant. No significant difference was observed
between male patients and female patients in this study.
Mean volume reduction vs. placebo at Day 84wasmen:23.7
SE 22.7 g, women 14.3 SE 10.2 g, N.S. There was no signif-
icant difference between patientswho had received previousTable 2 Limb volume measured as weight of displaced water;
mean and standard error (S.E.).
Place
Patients N Z
Limb volume as weight of displaced water [g; mean SE]
Baseline 2339.
Day 84 2331.
Change from baseline
Adjusted mean (SE)a 7.2
Difference to placebo
Adjusted mean (SE)a
95% confidence interval
p-value (ANCOVA)
a Means adjusted for centre effect and baseline values.treatment for CVI and those who had not. The mean volume
reduction vs. placebo at Day 84 was previous treatment:
-32.2 SE 15.9 g, no previous treatmente19.0 SE 11.5 g, N.S.
Calf circumference did not differ significantly between
placebo and AS195 groups. The mean difference between
groups were Day 21: 0.04 SE 0.12 cm (95% CI: 0.27, 0.19;
p Z 0.73), Day 42: 0.13 SE 0.13 cm (95% CI: 0.39, 0.13;
p Z 0.32) and Day 84: -0.17 SE 0.13 cm (95% CI: 0.44,
0.09; p Z 0.20).
Subjective CVI symptoms improved in both treatment
groups. AS195 was more effective than placebo, and for the
symptoms ‘tired, heavy legs’ and ‘pain in the legs’, the
absolute difference between groups increased approxi-
mately linearly over time. ‘Sensation of tension in the legs’
showed that the largest difference between groups was on
Day 42 (6.5 SD 3.0 mm; 95% CI: 12.3, 0.6; p Z 0.031;
ANCOVA). On Day 84, the adjusted mean differencechange from baseline to Day 84 (Full Analysis Set). All data:
bo AS195
122 N Z 126
1 SE 29.3 2306.2 SE 32.3
1 SE 30.4 2277.6 SE 31.9
SE 6.9 27.1 SE 6.8
19.9 SE 8.9
(37.5,2.3)
0.0268
Figure 2 Adjusted mean (SE) for change from baseline in limb volume over time; measured as weight of displaced water [g] (FAS).
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(95% CI: 9.0, 3.2) for ‘tired, heavy legs’, 3.5 SD 3.2 mm
(95% CI: 9.8, 2.8) for ‘sensation of tension in the legs’ and
6.6 SD 3.3 mm (95% CI: 13.1, 0.1; pZ 0.047) for ‘pain
in the legs’.
The time to improvement for all three subjective
symptoms was similar in the placebo and AS195 groups. In
the AS195 group, 55.6% felt an improvement in ‘pain in the
legs’ (placebo: 48.3%) during the first 20 days of treatment.
For all three symptoms, the improvement tended to appear
at similar times in the AS195 and placebo groups (p < 0.1;
Wilcoxon test).
The investigators rated global clinical efficacy signifi-
cantly better for patients randomised to AS195 (pZ 0.034,
Wilcoxon test). They assessed efficacy as good or satisfac-
tory in 71% of AS195 patients (placebo: 54%). The patient
ratings found similar results (AS195: 70% good or satisfac-
tory; placebo: 59%), but the difference between groups was
not significant (p Z 0.259) (see Fig. 3). In 37 patients,
investigators’ and patients’ assessments did not agree. In
16 of these cases, patients rated efficacy as not satisfac-
tory/bad, though seven had large volume reductions
(>50 g) and, in part, a pronounced improvement of
subjective symptoms. Overall, patient ratings agreed
satisfactorily with investigator’s assessments (Spearman
Correlation Coefficient rZ 0.73), but little with volumetry
(r Z 0.13) and subjective clinical symptoms (r z 0.43).
Safety
Overall, 73 patients (29% of the FAS) experienced AEs
during the treatment phase, 43 (35%) in the placebo and 30
(23.8%) in the AS195 group. Four placebo patients (3%) and
five AS195 patients (4%) experienced AEs that the investi-
gator judged were related to the study medication. Theseevents were aggravation of hypercholesterolaemia, dizzi-
ness, flatulence, malaise, urticaria and sleep disorder.
AEs which occurred in at least 1% of patients in any group
regardless of causality and more often in the AS195 than in
the placebo group were nasopharyngitis (nZ 3 vs. nZ 2 in
the placebo group), hypercholesterolaemia (n Z 2 vs.
n Z 1), oropharyngeal pain (n Z 2 vs. n Z 0), urticaria
(n Z 2 vs. n Z 0) and back pain (n Z 2 vs. n Z 0). The
urticaria cases are counterbalanced by cases of pruritus,
which occurred more often in the placebo than in the AS195
group (n Z 2 vs. n Z 0).
During the randomised treatment phase, eight patients
experienced serious AEs, all of which involved hospital-
isation. None was considered drug related. Four patients
had received AS195 (the AEs included retinal detachment;
abdominal pain; intravertebral disc protrusion; and
thrombophlebitis following stripping of saphenous vein) and
four placebo (the AEs were cerebrovascular accident;
peripheral oedema, skin ulcer, stasis dermatitis and
superinfection; cardiac failure; and lumbar radiculopathy).
One placebo patient experienced a serious AE during the
follow-up period (polymyalgia rheumatica).
Five placebo and one AS195 patient discontinued the study
because of AEs. These AEs were erysipelas, superinfection,
cerebrovascular accident, cardiac failure, skin ulcer, stasis
dermatitis, pain in extremity and peripheral oedema in the
placebo group and intervertebral disc protrusion in the AS195
group (discontinuation for multiple AEs possible).
Changes in laboratory values or vital signs did not reveal
safety signals (data not shown). The investigators’ and
patients’ global tolerability evaluations found no remark-
able or statistically significant differences between treat-
ment groups (p Z 0.533 and p Z 0.919, respectively;
Wilcoxon test). Tolerability was assessed as good or satis-
factory in 91e97% of patients.
Figure 3 Investigators’ and patients’ ratings of global clinical efficacy (FAS).
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In a previous Phase III study,9 360 and 720 mg day1 AS195
was found to be a safe and effective treatment for the
prolonged symptomatic control of CVI (Widmer grades IeII).
The study medication significantly improved the primary
clinical end point, leg oedema after 12 weeks of treatment.
Oedema was reduced by 76 ml (95% CI: 106 to 46 ml) vs.
placebo in the 360-mg group and by 100 ml (95% CI: 130
to70 ml) in the 720-mg group. The effect was consistent
across all other efficacy parameters, including the decrease
of leg circumference, the relief of subjective symptoms and
the global efficacy ratings by patients and investigators. A
further double-blind study confirmed that AS195 (360 mg
o.d.) reduced ankle and calf circumference, whereas these
parameters increased under placebo.8 In addition, AS195
improved microvascular blood flow and transcutaneous
oxygen pressure compared with placebo.
This study confirmed that AS195 consistently improved
objective and subjective endpoints in CVI patients to a larger
extent than placebo. It reduced lower limb volume, the
accompanying sensationof leg tensionandCVI-related legpain
significantly more than placebo. AS195 reduced lower limb
volume by 20 ml over placebo. This is less than found in the
earlier studywith thismedication,9 but in the rangeaCochrane
review and a recent overview observed in other phlebotonic
drugs.10,11 This overview, which primarily discussed error
sources of water displacement leg volumetry, found effects of
active therapy vs. placebo between þ7.5 ml (superiority of
placebo) and 100 ml (superiority of the active drug).
A volume reduction of 20mlmight appear small compared
with the entire volume of the calf of approximately 2500 ml.
This volume, however, contains large non-variable parts such
as bone and muscles. According to Marshall et al., oedema
only accumulates in an anatomical space of approximately
650ml, and the volume of a phlebological oedema that couldtheoretically be mobilised is approximately 220 ml.12,13 A
reduction of 20ml, thus corresponds to approximately 10% of
this maximum effect.
To judge the clinical relevance, we post hoc calculated
the standardised effect size (standardised mean difference
(SMD)) of volume reduction. We found an SMD of 0.28,
indicating a moderately pronounced and clinically relevant
effect.14 In the Cochrane review, the SMD ranged between
0.03 and 2.49.10
The study included a diverse patient population. This
becomes apparent when looking at age range (21e87
years), duration of CVI (0e49 years), baseline limb volume
(1646e3768 ml) and clinical symptoms, which encompassed
almost the entire 0e10 scale. Judging from their baseline
values, the patients were more severely affected by CVI
than those in the earlier Phase III study with AS195.9 This
diverse population makes our study results applicable to an
unselected population as seen in general or phlebological
practice.
Guidelines describe the place of pharmacological therapy
in CVI.15,16 Flavonoids such as AS195 are indicated in patients
with an inadequate response to compression therapy or if
compression is contraindicated. This may be the case in
patients with peripheral arterial occlusive disease or with
decompensatedcardiac failure.17 Furthermore,patientswith
arthritis of spine and/or extremitiesmaynot be able to put on
compression stockings, and patients with open wounds or
sensitivity disorders may not tolerate them. Flavonoids such
as AS195 are a treatment option here. They could be part of
a multimodal treatment concept for CVI patients, with
compression, drug treatment and surgical therapy. As
a perspective for the future, one study vs. compression
stockings or no treatment indicated that flavonoids may
prevent the deterioration of CVI over a period of 5 years.18 If
such results can be verified, this could extend the place of
flavonoids in the therapeutic arsenal for CVI.
Study with a Red-vine-leaf Extract in CVI 547In conclusion, AS195 was well tolerated and significantly
reduced the leg volume in patients with moderate-to-severe
CVI by approximately 20 ml more than placebo. Secondary
efficacy parameters also improved. Patients’ efficacy
assessment did not correlate well with other objective and
subjective parameters. It is unclearwhich aspects of therapy
patients assessed in expressing their opinions, andwhat they
expected.
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